Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

High-Shear Microplate

By Drug Discovery Trends Editor | March 1, 2010

FluxionFluxion Biosciences introduces a microplate for its BioFlux live cell imaging workstations, extending their shear flow limits to simulate a variety of pathological vascular conditions.  With the new High Shear Plate, the BioFlux systems can be an effective tool in thrombosis and platelet studies, cardiovascular and immunological drug screening and cell/bacteria adhesion research. 

The BioFlux 200 and 1000 platforms incorporate Fluxion’s unique Well Plate Microfluidic technology to enable plate-based live cell imaging under shear flow conditions that mimic those in the human body.  The BioFlux controller drives the flow of reagents and cells through microfluidic channels running between the wells.  Fully programmable changes to shear flow can be made in real time. 

The standard BioFlux 48-well plate is suited for studying normal flow conditions in the body, while the new High Shear Plate enables assays under the increased flow characteristic of diseased vasculature.  The new High Shear Plate is compatible with both the BioFlux 200 and the higher throughput, fully-integrated BioFlux 1000 system.  The presterlized SBS-standard 48-well plates can be used for up to 24 simultaneous flow experiments.

“In the presence of cardiovascular disease, where blood vessels can narrow considerably, shear stress is amplified,” explains Michael Schwartz, product manager for Fluxion.  “Because shear stress levels affect platelet and endothelial cell morphology and receptor expression, creating flow conditions for cellular assays is an important advantage.”
 
Date: November 10, 2009
Source: Fluxion Biosciences


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE